Document is current
Any future updates will be listed below
-
Authors
Thorvaldsdottir, Birna https://orcid.org/0000-0001-7372-9925
Mansouri, Larry
Sutton, Lesley-Ann
Nadeu, Ferran https://orcid.org/0000-0003-2910-9440
Meggendorfer, Manja
Parker, Helen
Brieghel, Christian https://orcid.org/0000-0002-1816-8106
Laidou, Stamatia https://orcid.org/0000-0002-4636-1579
Moia, Riccardo https://orcid.org/0000-0001-7393-1138
Rossi, Davide
Kotaskova, Jana https://orcid.org/0000-0003-1672-7346
Delgado, Julio https://orcid.org/0000-0002-5157-4376
Rodríguez-Vicente, Ana E. https://orcid.org/0000-0001-6516-2172
Benito, Rocío https://orcid.org/0000-0001-9781-4198
Rigolin, Gian Matteo https://orcid.org/0000-0002-8370-5190
Bonfiglio, Silvia
Scarfò, Lydia https://orcid.org/0000-0002-0844-0989
Mattsson, Mattias
Davis, Zadie https://orcid.org/0000-0001-6959-4853
Baliakas, Panagiotis https://orcid.org/0000-0002-5634-7156
Rapado, Inmaculada
Miras, Fatima
Martinez-Lopez, Joaquín
de la Serna, Javier
Hernández Rivas, Jesús María
Larráyoz, María José
Calasanz, María José
Smedby, Karin E.
Espinet, Blanca https://orcid.org/0000-0002-4294-8145
Puiggros, Anna
Bullinger, Lars https://orcid.org/0000-0002-5890-5510
Bosch, Francesc https://orcid.org/0000-0001-9241-2886
Tazón-Vega, Bárbara
Baran-Marszak, Fanny https://orcid.org/0000-0002-3723-2927
Oscier, David https://orcid.org/0000-0001-8486-2051
Nguyen-Khac, Florence
Zenz, Thorsten https://orcid.org/0000-0001-7890-9845
Terol, Maria Jose
Cuneo, Antonio
Hernández-Sánchez, María
Pospisilova, Sarka https://orcid.org/0000-0001-7136-2680
Gaidano, Gianluca https://orcid.org/0000-0002-4681-0151
Niemann, Carsten U. https://orcid.org/0000-0001-9880-5242
Campo, Elias https://orcid.org/0000-0001-9850-9793
Strefford, Jonathan C. https://orcid.org/0000-0002-0972-2881
Ghia, Paolo https://orcid.org/0000-0003-3750-7342
Stamatopoulos, Kostas https://orcid.org/0000-0001-8529-640X
Rosenquist, Richard https://orcid.org/0000-0002-0211-8788
-
Funding
Funding for this research was provided by:
Cancerfonden
Vetenskapsrådet
Radiumhemmets Forskningsfonder
- License Information
-
More Information
Article History
Received: 20 December 2024
Revised: 1 April 2025
Accepted: 8 April 2025
First Online: 24 April 2025
Competing interests
: PG: Honoraria/advisory board: AbbVie, Acerta/AstraZeneca, Adaptive, ArQule/MSD, BeiGene, CelGene/Juno, Gilead, Janssen, Loxo/Lilly, Sunesis. Research funding: AbbVie, Gilead, Janssen, Novartis, Sunesis; LS: advisory board AbbVie, AstraZeneca, Janssen; RR: honoraria/advisory board: AbbVie, AstraZeneca, Illumina, Janssen, Lilly and Roche; KS: honoraria/advisory board: AbbVie, Acerta/AstraZeneca, Gilead, Janssen. Research funding: AbbVie, Gilead, Janssen; PB: honoraria from Abbvie, Gilead and Janssen. Research funding from Gilead; GG: Advisory Board/Speaker’s bureau: Abbvie, AstraZeneca, Beigene, Hikma, Incyte, Johnson & Johnson, Lilly; LB: honoraria/advisory board: Abbvie, Amgen, Astellas, BMS/Celgene, Daiichi Sankyo, Gilead, Hexal, Janssen, Jazz Pharmaceuticals, Menarini, Novartis, Pfizer, Sanofi, Seattle Genetics. Research funding: Bayer, Jazz Pharmaceuticals; GMR: honoraria from Abbvie, AstraZeneca, Gilead and Janssen. Research funding from Gilead; CB: Honoraria/advisory board: AstraZeneca and Eli Lilly. CUN received research grants and/or honoraria from Abbvie, AstraZeneca, Janssen, Genmab, Beigene, Octapharma, MSD, Lilly, Synamics, CSL Behring, Takeda, Nofo Nordisk Foundation. The other authors declare no competing financial interests
